Foghorn Therapeutics Inc. announced that Cigall Kadoch, Ph.D., a co-founder of the Company, has accepted her appointment as an Investigator for the Howard Hughes Medical Institute (HHMI), effective on September 6, 2022. In accordance with HHMI's rules, she has resigned from Foghorn's Board of Directors, effective August 31, 2022. Dr. Kadoch has become Scientific Advisor to the Board and will continue to participate on Foghorn's Scientific Advisory Board.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.25 USD | -6.42% |
|
-12.65% | -18.60% |
May. 20 | Foghorn Therapeutics Prices $110 Million Offering of Shares, Pre-Funded Warrants | MT |
May. 06 | Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.60% | 290M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- FHTX Stock
- News Foghorn Therapeutics Inc.
- Press Release: Foghorn Therapeutics Announces Resignation of Cigall Kadoch from Board, Effective August 31, 2022